Allotex appoints Michael Mrochen as CEO

(Image credit: AdobeStock/Ashi)

Following market clearance in Europe, Canada, South Africa, Türkiye, and Australia, Allotex is actively executing a controlled market launch and preparing for expansion into additional regions. In a press release¹ received by our editors, the company shared that its regulatory efforts are progressing, including plans to submit an Investigational Device Exemption (IDE) in the United States in the second quarter of 2025 to develop further market access.

As the company prepares to expand and submit, Michael Mrochen, PhD, has been appointed as Chief Executive Officer. Mrochen is a co-founder of Allotex and a globally recognized innovator in ophthalmology. David Muller, who has served as CEO since Allotex’s founding, is supporting the planned transition and will remain with the company as Scientific Advisor.¹

Regarding his appointment, Mrochen said, “I’m honored to lead Allotex as we bring this breakthrough technology to more people. Our platform restores vision naturally—without glasses, without invasive surgery, and without compromising future treatment options.”¹

Muller spoke to this shift in leadership in the release.¹ He is quoted as saying, “Michael is the right person to lead Allotex into its next chapter. He’s strategic, experienced, and passionate about helping people see better.”

Allotex has developed a human collagen-based eye implant designed to help people over 40 restore their near vision without relying on reading glasses. The implant is placed just beneath the surface of the eye in an outpatient procedure that takes about 10 minutes. Made from natural human collagen rather than synthetic material, the implant is flexible, meaning it can be adjusted or removed if needed.

About Michael Mrochen, PhD

The company provided biography of Mrochen is as follows:

Mrochen is a globally recognized entrepreneur and innovation leader in ophthalmology, with a 30-year track record of transforming scientific breakthroughs into commercially successful technologies. He has founded and led multiple ventures in the vision care field, guided several to strategic exits, and played a key role in advancing products now used by eye care professionals worldwide. His contributions have earned recognition from leading ophthalmic societies, and he has been named multiple times as one of the most influential people in ophthalmology. He is widely considered a driving force in the future of vision correction.¹

Reference:

1. Allotex Accelerates into Commercial Phase and appoints Michael Mrochen as new CEO. Allotex. April 23, 2025. Accessed April 25, 2025.